|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||1,575.05 - 1,628.20|
|52 Week Range||1,404.55 - 1,962.00|
|Beta (3Y Monthly)||1.08|
|PE Ratio (TTM)||61.51|
|Forward Dividend & Yield||17.00 (1.10%)|
|1y Target Est||N/A|
A weekly round-up of the consumer news you need to know for the weekend, including Richard Branson slamming U.S. paid vacation policies, taxes on par, and asbestos found in Claire's make-up.
SHANGHAI/NEW YORK, Sept 28 (Reuters) - The U.S. Food and Drug Administration said on Friday it will no longer allow imports of drug ingredients or medicines made with ingredients produced by China's Zhejiang Huahai Pharmaceuticals, after a recall of one of its drugs that contained a probable carcinogen. The Chinese bulk manufacturer of the high blood pressure treatment valsartan recalled the product from consumers in the United States in July because an impurity linked to cancer had been detected. European authorities also said on Friday that they had found that Huahai did not comply with good manufacturing practices and that the company's factory in Linhai, China, was no longer authorized to produce valsartan.
FRANKFURT/BENGALURU, Sept 14 (Reuters) - European and North American regulators have found a second toxin that may cause cancer in humans in a commonly used blood pressure drug made by Chinese firm Zhejiang Huahai Pharmaceutical Co Ltd. Health regulators in the European Union, United States and Canada had already recalled drugs made with the company's active pharmaceutical ingredient valsartan after finding traces of the chemical N-nitrosodimethylamine (NDMA), considered a potential human carcinogen, in the medicine. On Thursday, the European Medicines Agency (EMA) said a different chemical, N-nitrosodiethylamine (NDEA), had been detected in products produced before 2012.